Literature DB >> 26746204

Analysis of EZH2: micro-RNA network in low and high grade astrocytic tumors.

Vikas Sharma1, Suvendu Purkait1, Sonam Takkar2, Prit Benny Malgulwar1, Anupam Kumar1, Pankaj Pathak1, Vaishali Suri1, Mehar C Sharma1, Ashish Suri3, Shashank Sharad Kale3, Ritu Kulshreshtha4, Chitra Sarkar5.   

Abstract

Enhancer of Zeste homologue2 (EZH2) is an epigenetic regulator that functions as oncogene in astrocytic tumors, however, EZH2 regulation remains little studied. In this study, we measured EZH2 levels in low (Gr-II,DA) and high grade (Gr-IV,GBM) astrocytic tumors and found significant increased EZH2 transcript level with grade(median DA-8.5, GBM-28.9).However, a different trend was reflected in protein levels, with GBMs showing high EZH2 LI(median-26.5) compared to DA (median 0.3). This difference in correlation of EZH2 protein and RNA levels suggested post-transcriptional regulation of EZH2, likely mediated by miRNAs. We selected eleven miRNAs that strongly predicted to target EZH2 and measured their expression. Three miRNAs (miR-26a-5p,miR27a-3p and miR-498) showed significant correlation with EZH2 protein, suggesting them as regulators of EZH2, however miR-26a-5p levels decreased with grade. ChIP analyses revealed H3K27me3 modifications in miR-26a promoter suggesting feedback loop between EZH2 and miR26a. We further measured six downstream miRNA targets of EZH2 and found significant downregulation of four (miR-181a/b and 200b/c) in GBM. Interestingly, EZH2 associated miRNAs were predicted to target 25 genes in glioma-pathway, suggesting their role in tumor formation or progression. Collectively, our work suggests EZH2 and its miRNA interactors may serve as promising biomarkers for progression of astrocytic tumors and may offer novel therapeutic strategies.

Entities:  

Keywords:  Astrocytic tumors; EZH2; Glioblastoma; MicroRNAs

Mesh:

Substances:

Year:  2016        PMID: 26746204     DOI: 10.1007/s10014-015-0245-1

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  9 in total

1.  C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Madhu Rajeshwari; Manmohan Singh; Vaishali Suri; Chitra Sarkar; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2018-01-22       Impact factor: 4.130

2.  EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.

Authors:  Yatao Yin; Shuwei Qiu; Xiangpen Li; Bo Huang; Yun Xu; Ying Peng
Journal:  J Neuroinflammation       Date:  2017-11-13       Impact factor: 8.322

Review 3.  Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Authors:  Anthos Christofides; Theodoros Karantanos; Kankana Bardhan; Vassiliki A Boussiotis
Journal:  Oncotarget       Date:  2016-12-20

4.  EZH2 overexpression is associated with poor prognosis in patients with glioma.

Authors:  Yanyang Zhang; Xinguang Yu; Ling Chen; Zhibin Zhang; Shiyu Feng
Journal:  Oncotarget       Date:  2017-01-03

5.  Role of the EZH2/miR-200 axis in STAT3-mediated OSCC invasion.

Authors:  Yu Wang; Wenyu Guo; Zhaoqing Li; Yansheng Wu; Chao Jing; Yu Ren; Minghui Zhao; Lingping Kong; Chao Zhang; Jiabin Dong; Yu Shuang; Shanshan Sun; Jinliang Chen; Chuanqiang Wu; Yu Qiao; Xin Qu; Xudong Wang; Lun Zhang; Rui Jin; Xuan Zhou
Journal:  Int J Oncol       Date:  2018-02-28       Impact factor: 5.650

6.  Identification of microRNA signature in different pediatric brain tumors.

Authors:  Marwa Tantawy; Mariam G Elzayat; Dina Yehia; Hala Taha
Journal:  Genet Mol Biol       Date:  2018-03-26       Impact factor: 1.771

7.  KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.

Authors:  Yiwei Wang; Jin Zang; Dongyong Zhang; Zhenxiang Sun; Bo Qiu; Xiaojie Wang
Journal:  Onco Targets Ther       Date:  2018-01-08       Impact factor: 4.147

8.  Identification and Expression Pattern of EZH2 in Pig Developing Fetuses.

Authors:  Baohua Tan; Linjun Hong; Jiaxin Qiao; Jian Zhou; Pingping Xing; Guanhao Yan; Enqin Zheng; Gengyuan Cai; Sixiu Huang; Zhenfang Wu; Ting Gu
Journal:  Biomed Res Int       Date:  2020-10-05       Impact factor: 3.411

9.  TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.

Authors:  Er Nie; Xin Jin; Faan Miao; Tianfu Yu; Tongle Zhi; Zhumei Shi; Yingyi Wang; Junxia Zhang; Manyi Xie; Yongping You
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.